• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

检测病毒整合位点热点的方法和软件。

Methodology and software to detect viral integration site hot-spots.

机构信息

Department of Biostatistics, University of California Los Angeles, School of Public Health, USA.

出版信息

BMC Bioinformatics. 2011 Sep 14;12:367. doi: 10.1186/1471-2105-12-367.

DOI:10.1186/1471-2105-12-367
PMID:21914224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3203353/
Abstract

BACKGROUND

Modern gene therapy methods have limited control over where a therapeutic viral vector inserts into the host genome. Vector integration can activate local gene expression, which can cause cancer if the vector inserts near an oncogene. Viral integration hot-spots or 'common insertion sites' (CIS) are scrutinized to evaluate and predict patient safety. CIS are typically defined by a minimum density of insertions (such as 2-4 within a 30-100 kb region), which unfortunately depends on the total number of observed VIS. This is problematic for comparing hot-spot distributions across data sets and patients, where the VIS numbers may vary.

RESULTS

We develop two new methods for defining hot-spots that are relatively independent of data set size. Both methods operate on distributions of VIS across consecutive 1 Mb 'bins' of the genome. The first method 'z-threshold' tallies the number of VIS per bin, converts these counts to z-scores, and applies a threshold to define high density bins. The second method 'BCP' applies a Bayesian change-point model to the z-scores to define hot-spots. The novel hot-spot methods are compared with a conventional CIS method using simulated data sets and data sets from five published human studies, including the X-linked ALD (adrenoleukodystrophy), CGD (chronic granulomatous disease) and SCID-X1 (X-linked severe combined immunodeficiency) trials. The BCP analysis of the human X-linked ALD data for two patients separately (774 and 1627 VIS) and combined (2401 VIS) resulted in 5-6 hot-spots covering 0.17-0.251% of the genome and containing 5.56-7.74% of the total VIS. In comparison, the CIS analysis resulted in 12-110 hot-spots covering 0.018-0.246% of the genome and containing 5.81-22.7% of the VIS, corresponding to a greater number of hot-spots as the data set size increased. Our hot-spot methods enable one to evaluate the extent of VIS clustering, and formally compare data sets in terms of hot-spot overlap. Finally, we show that the BCP hot-spots from the repopulating samples coincide with greater gene and CpG island density than the median genome density.

CONCLUSIONS

The z-threshold and BCP methods are useful for comparing hot-spot patterns across data sets of disparate sizes. The methodology and software provided here should enable one to study hot-spot conservation across a variety of VIS data sets and evaluate vector safety for gene therapy trials.

摘要

背景

现代基因治疗方法对治疗性病毒载体在宿主基因组中的插入位置的控制能力有限。载体整合可激活局部基因表达,如果载体插入到癌基因附近,可能会导致癌症。病毒整合热点或“常见插入位点”(CIS)被仔细研究,以评估和预测患者的安全性。CIS 通常通过插入的最小密度来定义(例如,在 30-100 kb 区域内插入 2-4 个),但不幸的是,这取决于观察到的 VIS 总数。这在比较不同数据集和患者之间的热点分布时存在问题,其中 VIS 数量可能会有所不同。

结果

我们开发了两种新的方法来定义热点,这些方法相对独立于数据集的大小。这两种方法都在基因组的连续 1 Mb“箱”中对 VIS 的分布进行操作。第一种方法“z 阈值”对每个箱中的 VIS 数量进行计数,将这些计数转换为 z 分数,并应用阈值来定义高密度箱。第二种方法“BCP”将贝叶斯变化点模型应用于 z 分数以定义热点。使用模拟数据集和来自五个已发表的人类研究的数据集(包括 X 连锁肾上腺脑白质营养不良(ALD)、CGD(慢性肉芽肿病)和 SCID-X1(X 连锁严重联合免疫缺陷)试验)比较了新颖的热点方法和传统的 CIS 方法。对两名患者(774 和 1627 个 VIS)和合并(2401 个 VIS)的人类 X 连锁 ALD 数据的 BCP 分析分别产生了 5-6 个热点,覆盖了基因组的 0.17-0.251%,包含了 VIS 的 5.56-7.74%。相比之下,CIS 分析产生了 12-110 个热点,覆盖了基因组的 0.018-0.246%,包含了 VIS 的 5.81-22.7%,这对应于随着数据集大小的增加而出现更多热点的情况。我们的热点方法使人们能够评估 VIS 聚类的程度,并从热点重叠的角度正式比较数据集。最后,我们表明,重新填充样本中的 BCP 热点与更大的基因和 CpG 岛密度重合,而不是与中位数基因组密度重合。

结论

z 阈值和 BCP 方法可用于比较不同大小数据集之间的热点模式。这里提供的方法和软件应该能够使人们研究各种 VIS 数据集之间的热点保存情况,并评估基因治疗试验中载体的安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/74ebedebb87a/1471-2105-12-367-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/ae2250b60f59/1471-2105-12-367-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/99c70887eb17/1471-2105-12-367-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/74ebedebb87a/1471-2105-12-367-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/ae2250b60f59/1471-2105-12-367-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/99c70887eb17/1471-2105-12-367-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51a3/3203353/74ebedebb87a/1471-2105-12-367-5.jpg

相似文献

1
Methodology and software to detect viral integration site hot-spots.检测病毒整合位点热点的方法和软件。
BMC Bioinformatics. 2011 Sep 14;12:367. doi: 10.1186/1471-2105-12-367.
2
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?X连锁重症联合免疫缺陷的基因治疗:我们目前的进展如何?
Hum Gene Ther. 2016 Feb;27(2):108-16. doi: 10.1089/hum.2015.137.
3
Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.通过在人类 SCID-X1 基因治疗试验中追踪逆转录病毒整合位点分析基因修饰祖细胞的动力学。
Blood. 2010 Jun 3;115(22):4356-66. doi: 10.1182/blood-2009-12-257352. Epub 2010 Mar 12.
4
Curing genetic disease with gene therapy.用基因疗法治疗遗传疾病。
Trans Am Clin Climatol Assoc. 2014;125:122-8; discussion 128-9.
5
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.慢病毒基因治疗联合小剂量白消安治疗 X-连锁重症联合免疫缺陷病 1 型婴儿
N Engl J Med. 2019 Apr 18;380(16):1525-1534. doi: 10.1056/NEJMoa1815408.
6
Gene therapy of inherited immunodeficiencies.遗传性免疫缺陷的基因治疗。
Expert Opin Biol Ther. 2008 Apr;8(4):397-407. doi: 10.1517/14712598.8.4.397.
7
Gene therapy for inherited immunodeficiency.遗传性免疫缺陷的基因治疗。
Expert Opin Biol Ther. 2014 Jun;14(6):789-98. doi: 10.1517/14712598.2014.895811. Epub 2014 Mar 8.
8
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.慢病毒载体在临床前模型和临床试验中的常见整合位点反映了良性的整合偏向,而不是致癌性选择。
Blood. 2011 May 19;117(20):5332-9. doi: 10.1182/blood-2010-09-306761. Epub 2011 Mar 14.
9
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.载体整合是非随机且成簇的,并影响X连锁重症联合免疫缺陷病基因治疗中淋巴细胞生成的命运。
J Clin Invest. 2007 Aug;117(8):2225-32. doi: 10.1172/JCI31659.
10
Quantitative shearing linear amplification polymerase chain reaction: an improved method for quantifying lentiviral vector insertion sites in transplanted hematopoietic cell systems.定量剪切线性扩增聚合酶链反应:一种用于定量移植造血细胞系统中慢病毒载体插入位点的改进方法。
Hum Gene Ther Methods. 2015 Feb;26(1):4-12. doi: 10.1089/hgtb.2014.122. Epub 2015 Feb 5.

引用本文的文献

1
Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs.比较用于检测腺相关病毒(AAV)基因治疗构建体病毒整合的分子方法和计算方法。
Mol Ther Methods Clin Dev. 2023 May 4;29:395-405. doi: 10.1016/j.omtm.2023.04.009. eCollection 2023 Jun 8.
2
A Graph Based Framework to Model Virus Integration Sites.一种基于图形的病毒整合位点建模框架。
Comput Struct Biotechnol J. 2015 Nov 30;14:69-77. doi: 10.1016/j.csbj.2015.10.006. eCollection 2016.
3
Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients.

本文引用的文献

1
Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.慢病毒载体在临床前模型和临床试验中的常见整合位点反映了良性的整合偏向,而不是致癌性选择。
Blood. 2011 May 19;117(20):5332-9. doi: 10.1182/blood-2010-09-306761. Epub 2011 Mar 14.
2
Genetic therapy for beta-thalassemia: from the bench to the bedside.β-地中海贫血的基因治疗:从实验室到临床。
Hematology Am Soc Hematol Educ Program. 2010;2010:445-50. doi: 10.1182/asheducation-2010.1.445.
3
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.
重组腺相关病毒整合与非人灵长类动物和患者的肝脏遗传毒性无关。
Mol Ther. 2016 Jun;24(6):1100-1105. doi: 10.1038/mt.2016.52. Epub 2016 Mar 7.
4
Meta-Analysis of DNA Tumor-Viral Integration Site Selection Indicates a Role for Repeats, Gene Expression and Epigenetics.DNA肿瘤病毒整合位点选择的Meta分析表明重复序列、基因表达和表观遗传学的作用。
Cancers (Basel). 2015 Nov 10;7(4):2217-35. doi: 10.3390/cancers7040887.
5
The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.人嗜T淋巴细胞病毒1型(HTLV-1)克隆性、前病毒结构及基因组整合位点在成人T细胞白血病/淋巴瘤中的作用
Blood. 2014 Jun 19;123(25):3925-31. doi: 10.1182/blood-2014-02-553602. Epub 2014 Apr 15.
6
Dynamics of HSPC repopulation in nonhuman primates revealed by a decade-long clonal-tracking study.通过长达十年的克隆追踪研究揭示非人灵长类动物 HSPC 重编程动力学。
Cell Stem Cell. 2014 Apr 3;14(4):473-85. doi: 10.1016/j.stem.2013.12.012.
7
Retroviral integrations in gene therapy trials.逆转录病毒在基因治疗试验中的整合。
Mol Ther. 2012 Apr;20(4):709-16. doi: 10.1038/mt.2011.289. Epub 2012 Jan 17.
采用慢病毒载体的造血干细胞基因疗法治疗X连锁肾上腺脑白质营养不良症
Science. 2009 Nov 6;326(5954):818-23. doi: 10.1126/science.1171242.
4
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.使用人类和小鼠T细胞受体的基因疗法介导癌症消退,并靶向表达同源抗原的正常组织。
Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.
5
Gene therapy fulfilling its promise.基因疗法正在兑现其承诺。
N Engl J Med. 2009 Jan 29;360(5):518-21. doi: 10.1056/NEJMe0809614.
6
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.4例X连锁重症联合免疫缺陷病(SCID-X1)患者在逆转录病毒介导的基因治疗后发生插入性致癌作用。
J Clin Invest. 2008 Sep;118(9):3132-42. doi: 10.1172/JCI35700.
7
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.嗜异性小鼠白血病病毒相关病毒的整合位点偏好性,一种与前列腺癌相关的新型人类逆转录病毒。
J Virol. 2008 Oct;82(20):9964-77. doi: 10.1128/JVI.01299-08. Epub 2008 Aug 6.
8
A fast Bayesian change point analysis for the segmentation of microarray data.一种用于微阵列数据分割的快速贝叶斯变化点分析方法。
Bioinformatics. 2008 Oct 1;24(19):2143-8. doi: 10.1093/bioinformatics/btn404. Epub 2008 Jul 29.
9
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.γ逆转录病毒介导的重症联合免疫缺陷病X1型(SCID-X1)的校正与体内载体整合位点分布偏向有关。
J Clin Invest. 2007 Aug;117(8):2241-9. doi: 10.1172/JCI31661.
10
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.载体整合是非随机且成簇的,并影响X连锁重症联合免疫缺陷病基因治疗中淋巴细胞生成的命运。
J Clin Invest. 2007 Aug;117(8):2225-32. doi: 10.1172/JCI31659.